Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody

Jianjun Chen†1,2, Fenghua Zhang†1, Fang Fang†1, Haiyan Chang1 and Ze Chen*1,2,3

Address: 1College of Life Science, Hunan Normal University, Changsha 410081, Hunan, China, 2State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, Hubei, China and 3Shanghai Institute of Biological Products, Shanghai 200052, China

Email: Jianjun Chen - chenjj126@126.com; Fenghua Zhang - fhz2005@vip.163.com; Fang Fang - fangfangc@263.net; Haiyan Chang - chang_haiyan@hotmail.com; Ze Chen* - chenze2005@263.net

* Corresponding author †Equal contributors

Abstract

Background: Maternal antibody is the major form of protection against disease in early life; however, its presence interferes with active immunization of offspring. In order to overcome the immunosuppression caused by maternal antibody, several immune strategies were explored in this paper using mouse model and influenza vaccines.

Results: The results showed that: i) when the offspring were immunized with the same vaccine as their mothers, whether inactivated or DNA vaccine, the presence of maternal antibody inhibited offspring immune response and the offspring could not be protected from a lethal influenza virus infection; ii) when the offspring, born to mothers immunized with inactivated vaccine, were immunized with NA DNA vaccine, the interference of maternal antibody were overcome and the offspring could survive a lethal virus challenge; iii) when the offspring were immunized with different DNA vaccine from that for their mothers, the interference of maternal antibody were also overcome. In addition, high-dose inactivated vaccine in maternal immunization caused partial inhibition in offspring when the offspring were immunized with HA DNA vaccine, while lower dose caused no significant immunosuppression.

Conclusion: To avoid the interference of maternal antibody in influenza vaccination of offspring, mothers and their offspring shall not be immunized with the same vaccine. If mothers are immunized with inactivated vaccine, NA DNA vaccine for the offspring shall be effective; and if mothers are immunized with HA (NA) DNA, NA (HA) DNA for the offspring shall be effective.

Background

Influenza is a highly contagious acute respiratory disease caused by infection of the host respiratory tract with influenza virus [1]. The virus is transmitted in the population of all the age groups, especially in the newborns. The prevention of influenza is currently achieved by subcutaneous injection of inactivated trivalent influenza vaccine. However, because of the immaturity of immune system, effective immune response could not be induced in newborns and therefore vaccination in this age group could
not get a satisfactory effect [2,3]. The problem can be solved well by maternal immunization, which can provide the offspring with high titer of maternal antibody [4]. Maternal immunization is beneficial to the offspring, whereas, it also brings the problem of immunosuppression. The presence of the maternal antibody inhibits the offspring immune response to specific antigen [5–7], and the long-lasting immunosuppression often delays the vaccination of the offspring. In young infants, a period susceptible to influenza exists when the maternal antibody titer is too low to provide immunoprotection but is enough to inhibit the active immune response to vaccines. Thus, it is necessary to develop an effective immune strategy to overcome the immunosuppression caused by maternal antibody.

In this paper, we explored the interference of maternal antibody in offspring immune response to influenza vaccines as well as the immune strategy to overcome the interference. We found that, when the offspring were immunized with the same vaccine as their mothers, whether inactivated or DNA vaccine, the active immune response in offspring would be inhibited by the presence of maternal antibody. However, the interference could be overcome under the following situations: immunization of offspring with Neuraminidase (NA) DNA vaccine when the mother were once immunized with inactivated vaccine from that for their mothers, i.e. Hemagglutinin (HA) DNA or NA DNA. These results provided an experimental basis for overcoming the immunosuppression caused by maternal antibody in clinic.

Results

Maternal immunization with inactivated vaccine inhibited the effect of inactivated vaccine on protection of offspring

In order to explore whether maternal immunization with inactivated influenza vaccine interferes with the immune effect of inactivated influenza vaccine in offspring, we performed the following test. The female BALB/c mice aged 6–8 weeks were divided into seven groups. In control group, all the mice were unimmunized, including their natal offspring. In three of the six experimental groups, the female mice were unimmunized, but their offspring were immunized with 1.0 μg, 0.1 μg and 0.01 μg of inactivated influenza virus A/PR/8/34 vaccine at age of 1 week respectively, and boosted 3 weeks later with the vaccine at the same dose as primed. In other three experimental groups, the female mice were immunized twice, 3 weeks apart, with 1.0 μg, 0.1 μg and 0.01 μg of inactivated influenza vaccines respectively, and the offspring were immunized twice at age of 1 and 4 weeks respectively, with the same vaccine at the same doses as those for their mothers. The sera of offspring were collected by tail vein bleeding 3 weeks after primary immunization and 1 week after booster respectively and determined for IgG antibody titer by ELISA. As shown in Table 1, when the mothers were immunized with 1.0 μg and 0.1 μg of inactivated vaccine, the antibody titers in their offspring after booster were lower than those after the primary immunization. However, when the female mice were immunized with 0.01 μg of inactivated vaccine, the antibody titers in their offspring after booster were slightly higher. In contrast, the offspring of the unimmunized mothers had higher antibody levels after booster than after the primary immunization.

Table 1: Influence of maternal antibodies on protective effect of offspring immunized with the same inactivated vaccine as their mothers

| Dose (μg) | Serum IgG titers b in offspring ELISA (2 n)c | Lung virus titers b (log10 TCID50) | Survival offspring/Tested offspring (3 weeks) |
|-----------|---------------------------------------------|-----------------------------------|----------------------------------------------|
| Female mice | Offspring | 21 days after primary immunization | 7 days after booster | |
| 1.00 | 1.00 | 14.8 ± 0.50 | 13.3 ± 0.30 | 3.7±0.00 | 0/7 |
| 0.10 | 0.10 | 13.8 ± 0.90 | 11.5 ± 0.60 | 4.7 ± 0.23 | 0/7 |
| 0.01 | 0.01 | 9.7 ± 0.60 | 11.3 ± 0.50 | 4.8 ± 0.71 | 0/7 |
| Unimmunized | 1.00 | 14.3 ± 0.60 | 16.7 ± 0.60 | ND* | 7/7* |
| Unimmunized | 0.10 | 12.7 ± 0.60 | 16.0 ± 1.00 | 3.4 ± 0.54* | 6/6* |
| Unimmunized | 0.01 | 11.3 ± 0.50 | 13.0 ± 0.00 | 3.4 ± 0.54* | 5/6* |
| Unimmunized | Unimmunized | <1 | <1 | 5.4 ± 0.10 | 0/7 |

a The female mice were immunized twice, 3 weeks apart, with various doses of inactivated vaccine. The offspring were immunized at ages of 1 and 4 weeks, respectively, with the same vaccine as their mothers. Serum samples from offspring were collected 3 weeks after primary immunization and 1 week after booster. The serum antibody titers were measured by ELISA. One week after booster, the offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD50). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.

b Values represent mean ± S.D. of each group.

c The serum samples were diluted 2-fold serially and “n” represents the dilution factor.

* Significant difference (p < 0.05). ND: virus not detected
All the offspring in experimental groups were challenged with a lethal dose (20 × LD₅₀) of influenza virus strain A/PR/8/34 by intranasal drip 1 week after the booster. At least three offspring in each group were dissected 3 days after challenge, and their lungs were taken out for virus titration. The rest offspring were observed for 3 weeks to calculate the survival rate. As shown in Table 1, when both the mothers and their offspring were immunized twice with inactivated influenza vaccine, regardless of the doses, all the offspring showed high lung virus titer and died within 2 weeks after challenge. However, when the female mice were unimmunized, their offspring immunized with 1.0 μg, 0.1 μg and 0.01 μg of inactivated influenza vaccine had the survival rates of 100%, 100% and 83.3% respectively (Table 1 and Figure 1A), with significantly lower lung virus titers than offspring in control group. All offspring in control group died within 7 days after challenge, and their lung virus titers were the highest among the seven groups.

The above-mentioned results indicated that the maternal immunization with inactivated vaccine inhibited the immune response induced by the same vaccine in offspring.

**Maternal immunization with DNA vaccine inhibited the effect of the same DNA vaccine on protection of offspring**

In order to explore whether the maternal immunization with DNA inhibits the immune effect of the same vaccine in offspring, we performed the following test. The female BALB/c mice aged 6–8 weeks were divided into five groups. In control group, both the female mice and their offspring were unimmunized. In two of the four experimental groups, the female mice were immunized, but their offspring were immunized at age of 1 week with 30 μg of HA DNA and 30 μg of NA DNA, respectively, and boosted 3 weeks later with the same DNA vaccine at the same dose as primed. In other two experimental groups, the female mice were immunized twice (at a 3-week interval) with 30 μg of HA DNA and 30 μg of NA DNA, respectively, and the offspring were immunized twice at ages of 1 and 4 weeks respectively, with the same DNA vaccine at the same dose as that for their mothers.

The sera of offspring were collected by tail vein bleeding both 3 weeks after primary immunization and 1 week after booster and determined for HA or NA antibody titer. As shown in Table 2, when both the mothers and their offspring were immunized with HA DNA, the HA antibody titers in offspring after booster were lower either than those after primary immunization with HA DNA, the NA antibody titers of offspring after booster were also lower either than those after primary immuniza-

---

**Figure 1**

Survival of offspring after lethal A/PR8/34 virus challenge. The offspring were vaccinated as described in result section. One week after second immunization, the offspring were challenged with a lethal dose of A/PR8/34 (20 × LD₅₀). Survival rates of mice were measured after viral challenge. Panel A: (A1) Immunization of both mothers and the offspring with 1.0 μg of inactivated vaccine; (A2) Immunization of both mothers and the offspring with 0.1 μg of inactivated vaccine; (A3) Immunization of both mothers and the offspring with 0.01 μg of inactivated vaccine; (A4) Immunization of offspring born to unimmunized mothers with 1.0 μg of inactivated vaccine; (A5) Immunization of offspring born to unimmunized mothers with 0.1 μg of inactivated vaccine; (A6) Immunization of offspring born to unimmunized mothers with 0.01 μg of inactivated vaccine; (A7) Negative control. Panel B: (B1) Immunization of both mothers and the offspring with 30 μg of HA DNA; (B2) Immunization of offspring born to unimmunized mothers with 30 μg of HA DNA; (B3) Immunization of both mothers and the offspring with 30 μg of NA DNA; (B4) Immunization of offspring born to unimmunized mothers with 30 μg of NA DNA; (B5) Negative control. Panel C: (C1) Immunization of mothers with 1.0 μg of inactivated vaccine and the offspring with 30 μg of HA DNA; (C2) Immunization of mothers with 0.1 μg of inactivated vaccine and the offspring with 30 μg of HA DNA vaccine; (C3) Immunization of mothers with 0.01 μg of inactivated vaccine and the offspring with 30 μg of HA DNA vaccine; (C4) Immunization of mothers with 1.0 μg of inactivated vaccine and the offspring with 30 μg of NA DNA; (C5) Immunization of mothers with 0.1 μg of inactivated vaccine and the offspring with 30 μg of NA DNA; (C6) Immunization of mothers with 0.01 μg of inactivated vaccine and the offspring with 30 μg of NA DNA; (C7) Negative control. Panel D: (D1) Immunization of mothers with 30 μg of HA DNA and the offspring with 30 μg of NA DNA; (D2) Immunization of mothers with 30 μg of NA DNA and the offspring with 30 μg of HA DNA; (D3) Negative control. *Significant differences (p < 0.05) compared to negative controls as determined by Log Rank test.
mothers as well.

The female BALB/c mice aged 6–8 weeks were divided into four groups. In control group, both the female mice and their offspring were unimmunized. In the three experimental groups, the female mice were immunized twice, 3 weeks apart, with 1.0 μg, 0.1 μg and 0.01 μg of inactivated influenza vaccine respectively, and their offspring were immunized with 30 μg of HA DNA at age of 1 week and boosted 3 weeks later.

The sera of offspring were collected by tail vein bleeding 3 weeks after primary immunization and 1 week after booster respectively and determined for HA antibody titer by ELISA. As shown in Table 3, when the mothers were immunized with 1.0 μg of inactivated vaccine, the antibody titer in offspring after booster was only slightly higher than those after primary immunization. When the mothers were immunized with 0.1 μg and 0.01 μg of inactivated vaccine, the antibody titer in offspring after booster was lower than that after primary immunization. The offspring in all groups were challenged with a lethal dose of influenza virus as described above. As shown in Table 3, when the mothers were immunized with 1.0 μg of inactivated vaccine and their offspring with HA DNA, the protective rates of offspring were 50% and 42.8% respectively (p > 0.05). However, when the female mice were immunized with 0.01 μg of inactivated vaccine, the protective rate of offspring was 85.7% (p < 0.05) (Table 3 and Figure 1C). The offspring in the three experimental groups had significantly lower lung virus titers than control mice, and the offspring born to the mothers immunized with 0.01 μg of inactivated vaccine had the lowest titer among the three groups. The results indicated the dose-dependent inhibition of maternal immunization with inactivated vaccine on immunization of offspring with HA DNA.

Table 2: Influence of maternal antibodies on protective effect of offspring immunized with the same DNA vaccine as that for their mothersa

| Plasmid | Serum IgG titersb in offspring | Lung virus titersb (log10 TCID50) | Survival offspring/ Tested offspring (3 weeks) |
|---------|-------------------------------|---------------------------------|-----------------------------------------------|
| Plasmid for female mice | Plasmid for offspring | 21 days after primary immunization | 7 days after booster | 21 days after primary immunization | 7 days after booster | 3 weeks after challenge |
| 30 μg HA | 30 μg HA | 15.0 ± 0.00 | 13.3 ± 0.60 | 4.3 ± 0.35 | 0/7 |
| Unimmunized | 30 μg HA | 11.3 ± 0.50 | 14.3 ± 0.50 | 4.0 ± 0.58a | 5/7a |
| 30 μg NA | 30 μg NA | 5.6 ± 0.90 | 3.3 ± 0.60 | 4.0 ± 0.70 | 2/7 |
| Unimmunized | 30 μg NA | 4.6 ± 0.60 | 8.5 ± 0.70 | 2.8 ± 0.35a | 7/7a |
| Unimmunized | Unimmunized | <1 | <1 | <3 | <3 |
| 30 μg HA | 30 μg NA | 5.7 ± 0.00 | 0/7 |

a Female mice were immunized twice, 3 weeks apart, with 30 μg HA DNA or 30 μg NA DNA. The offspring were immunized at ages of 1 and 4 weeks, respectively, with the same vaccine as their mothers. Serum samples from offspring were collected 3 weeks after primary immunization and 1 week after booster. The anti-HA antibody titers were measured by ELISA. The anti-NA antibody titers were measured by NI assay. One week after booster, the offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD50). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.

b Values represent mean ± S.D. of each group.

The above-mentioned results indicated that the maternal antibody induced by DNA vaccine inhibited the immune protection by lung virus titers and survival rates, as described above. As shown in Table 2, when both the female mice and their offspring were immunized with HA DNA, the survival rate of offspring was 0%; and when both with NA DNA, the survival rate of offspring was 28.6%. However, when the female mice were unimmunized, the offspring immunized with HA DNA and NA DNA showed the survival rates of 71.4% and 100%, respectively (Table 2 and Figure 1B), and they had significantly lower lung virus titers than the offspring in control group, and lower titers than those born to immunized mothers as well.

The above-mentioned results indicated that the maternal antibody induced by DNA vaccine inhibited the immune protection of the same DNA vaccine on protection of offspring.

Maternal immunization with inactivated vaccine partially inhibited the effect of HA DNA vaccine on protection of offspring

The female BALB/c mice aged 6–8 weeks were divided into four groups. In control group, both the female mice and their offspring were unimmunized. In the three experimental groups, the female mice were immunized twice, 3 weeks apart, with 30 μg HA DNA or 30 μg NA DNA. The offspring were immunized at ages of 1 and 4 weeks, respectively, with the same vaccine as their mothers. Serum samples from offspring were collected 3 weeks after primary immunization and 1 week after booster. The anti-HA antibody titers were measured by ELISA. The anti-NA antibody titers were measured by NI assay. One week after booster, the offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD50). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.
Maternal immunization with inactivated vaccine could not inhibit the effect of NA DNA vaccine on protection of offspring

The BALB/c mice aged 6–8 weeks were divided into four groups. In control group, both the female mice and their offspring were unimmunized. In three experimental groups, the female mice were immunized twice, 3 weeks apart, with 1.0 μg, 0.1 μg and 0.01 μg of inactivated influenza vaccine respectively, and their offspring were immunized with 30 μg of NA DNA at age of 1 week and boosted 3 weeks later.

The sera of offspring were collected by tail vein bleeding both 3 weeks after primary immunization and 1 week after booster and determined for NA antibody titer by NI assay. As shown in Table 3, the NA antibody titers of offspring after booster were much higher than those after primary immunization. The offspring in experimental groups were challenged with a lethal dose of influenza virus as described above. After immunized with NA DNA, all the offspring born to the immunized mothers showed a survival rate of 100% (Table 3 and Figure 1C), and correspondingly, their lung virus titers were far lower than that in control group. The results showed no influence of maternal immunization with inactivated vaccine on immunization of offspring with NA DNA.

Maternal immunization with one kind of DNA vaccine could not inhibit the effect of another kind of DNA vaccine on protection of offspring

In order to explore whether immunization of female mice and their offspring with different DNA vaccines could overcome the inhibition of maternal antibody, we performed the following test. The BALB/c mice aged 6–8 weeks were divided into three groups. In control group, both the female mice and their offspring were unimmunized. In one experimental group, the female mice were immunized twice, 3 weeks apart, with 30 μg of HA DNA, and their offspring were immunized with 30 μg of NA DNA at age of 1 week and boosted 3 weeks later. In another experimental group, the female mice were immunized twice, 3 weeks apart, with 30 μg of NA DNA, and their offspring were immunized with 30 μg of HA DNA at age of 1 week and boosted 3 weeks later.

The sera of offspring were collected by tail vein bleeding both 3 weeks after primary immunization and 1 week after booster and determined for HA or NA antibody titer. As shown in Table 4, when the mothers were immunized with NA DNA, and their offspring with HA DNA, the HA antibody titers of offspring after booster were higher than those after primary immunization. Similarly, when the mothers were immunized with HA DNA, and their offspring with NA DNA, the NA antibody titers of offspring after booster were higher than those after primary immunization. The offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD50). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.

### Table 3: Protection against a lethal influenza virus challenge in offspring immunized with DNA vaccine born to the mothers immunized with inactivated vaccine

| Dose (μg) of Inactivated vaccine for female mice | Plasmid for offspring | ELISA (2ⁿ) | NI assay (2ⁿ) | Lung virus titers (log₁₀ TCID₅₀) | Survival offspring/Tested offspring (3 weeks) |
|-----------------------------------------------|-----------------------|------------|---------------|-------------------------------|---------------------------------------------|
|                                              |                       | 21 days after primary immunization | 7 days after booster | 21 days after primary immunization | 7 days after booster |                                             |
| 1.00 30 μg HA                                | 14.8 ± 0.50           | 13.3 ± 0.30 | 3.3 ± 0.35    | 3/6                           |
| 0.10 30 μg HA                                | 11.7 ± 0.50           | 12.5 ± 0.60 | 3.8 ± 0.23²   | 3/7                           |
| 0.01 30 μg HA                                | 11.3 ± 0.60           | 13.0 ± 0.00 | 3.0 ± 0.71²   | 6/7                           |
| 1.00 30 μg NA                                | 4.3 ± 0.60            | 7.0 ± 1.00  | 1.9 ± 0.58²   | 7/7                           |
| 0.10 30 μg NA                                | 3.7 ± 0.60            | 7.2 ± 0.80  | 1.5 ± 0.24²   | 7/7                           |
| 0.01 30 μg NA                                | 4.3 ± 0.60            | 8.0 ± 1.00  | 0.9 ± 0.83²   | 6/6²                          |
| Unimmunized Unimmunized                      | <1                    | <1          | <3            | 5.3 ± 0.35                    | 0/7                          |

*Female mice were immunized twice, 3 weeks apart, with various doses of inactivated vaccine. The offspring were immunized with 30 μg HA or 30 μg NA at ages of 1 and 4 weeks respectively. Serum samples from offspring were collected 3 weeks after primary immunization and 1 week after booster. The anti-HA antibody titers were measured by ELISA. The anti-NA antibody titers were measured by NI assay. One week after booster, the offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD₅₀). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.

²Values represent mean ± S.D. of each group.

n The serum samples were diluted 2-fold serially and "n" represents the dilution factor.

²Significant difference (p < 0.05)
Table 4: Protection against a lethal influenza virus challenge in offspring immunized with different DNA vaccine from that for their mothers a

| Plasmid for female mice | Plasmid for offspring | ELISA (2n)c | NI assay (2n)c | Lung virus titerb (log_{10} TCID_{50}) | Survival offspring/ Tested offspring (3 weeks) |
|-------------------------|-----------------------|-------------|---------------|-------------------------------------|-----------------------------------------------|
| 30 μg HA                | 30 μg NA              | 4.3 ± 0.60  | 7.0 ± 1.40    | 1.2 ± 0.57*                         | 7/7*                                          |
| 30 μg NA                | 30 μg HA              | 12.0 ± 0.60 | 15.7 ± 0.60   | 3.8 ± 0.23*                         | 7/7*                                          |
| Unimmunized            | Unimmunized           | <3          | <3            | 5.5 ± 0.16                          | 0/7                                           |

a Female mice were immunized twice, 3 weeks apart, with 30 μg HA DNA or 30 μg NA DNA. The offspring were immunized with the different vaccines from that for their mothers at ages of 1 and 4 weeks respectively. Serum samples from offspring were collected 3 weeks after primary immunization and 1 week after booster. The anti-HA antibody titers were measured by ELISA. The anti-NA antibody titers were measured by NI assay. One week after booster, the offspring were challenged with a lethal dose of A/PR/8/34 (20 × LD_{50}). Lungs were taken out from at least three mice in each group 3 days after challenge for virus titration by standard MDCK assay. Survival rates of mice were measured 3 weeks after challenge.

b Values represent mean ± S.D. of each group.

c The serum samples were diluted 2-fold serially and "n" represents the dilution factor.

*Significant difference (p < 0.05)

of influenza virus as described above. As shown in Table 4, all the survival rates of offspring in the two experimental groups were 100% (also shown in Figure 1D), and correspondingly, their lung virus titers were significantly lower than that of offspring in blank control group. It indicated that the immunization of female mice and their offspring with different DNA vaccines could overcome the interference of maternal antibody in offspring.

**Discussion**

Maternal immunization is the major form of protection against many infectious diseases in early life, since IgG Ab can transfer from pregnant women to their foetus through placenta, colostrums and milk [8-11]. Both pregnant women and young infants were found to be vulnerable to serious sequelae of influenza infection [4]. Vaccination in pregnant women is beneficial to both mother and infant. It has been shown that, after women in the last trimester of pregnancy were given trivalent inactivated influenza virus vaccine, high IgG antibody titers to maternal vaccine antigens were detected in cord and infant serum [12]. The passive antibodies given by mother could delay the onset and decrease the severity of influenza disease in young infants [13]. Inactivated influenza vaccine is currently recommended by the US CDC (Centers for Disease Control and Prevention in Atlanta, Georgia, USA) for all pregnant women, especially those in the second or third trimester during influenza seasons or those with high risk conditions [14]. Besides inactivated vaccine, we have found that immunization of mothers with plasmid DNAs encoding influenza HA or NA gene could afford protection to the offspring from a lethal viral infection [15].

On the other hand, the presence of maternal antibody can inhibit the active immune response of offspring. The titer of maternal antibody decreases gradually with the growth of offspring, but even low titer can interfere with the active immune response in offspring [16]. Van Maanen et al. [7] have studied the influence of maternal antibody induced by equine influenza vaccine on the immune effect of the same vaccine in foals. The result showed that the maternal antibody interfered with the vaccination of influenza vaccine in foals aged 24–28 weeks. Radu et al. [6] have discovered that the immunization of female mice with inactivated influenza virus WSN (A/WSN/32, H1N1) vaccine inhibited the immune effect of the same vaccine in their offspring. Apart from influenza vaccine, the presence of maternal antibody also showed influence on immunization of offspring with many other vaccines. Albrecht et al. [17] have investigated the influence of maternal antibody on the vaccination of live attenuated measles vaccine in 34 infants aged 12 months. The seroconversion of measles antibody was not observed in the children with high maternal antibody titers but observed in the children with lower maternal antibody titers, though the induced antibody titers were significantly lower than those of children without maternal antibody. Letson et al. [18] have found that, when immunized with inactivated hepatitis A virus (HAV) vaccine within one year old, the maternal antibody-positive children had the significantly lower HAV antibody titer than the maternal antibody-negative children. The passively acquired antibody has also been proved a major interfering factor of immunization with respiratory syncytial virus (RSV) vaccine in offspring. In the study conducted by Murphy et al. [19], when cotton rats were injected with the antisera against RSV, and then
immunized with the recombinant poxvirus expressing the F (fusion) and G (large) proteins of RSV, the injected antisera inhibited production of the F and G antibodies induced by recombinant poxvirus vaccine. It is thus clear that, though maternal antibody can protect offspring against infectious disease, it can inhibit the active immune response in offspring. Both the protective and inhibitory effects diminish gradually with the growth of offspring. This diminishing period is the infection-susceptible period for offspring.

In our study, we also explored the inhibition of maternal antibody on the immunization of offspring. The influence of maternal antibody on the immunization of offspring was studied by determination of antibody titer and by virus challenge test. The immunosuppression was observed when the mothers and their offspring were immunized with the same vaccines, either inactivated or DNA vaccines. Few or even no offspring survived the lethal virus challenge (see Table 1 and 2). The result indicated that immunization of female mice and their natal offspring with the same vaccine may bring strong inhibition on offspring immune response.

Ways have been looking for to deal with the interference of maternal antibody. The first one is by vaccinating the offspring when maternal antibody declines to a certain extent [20], or by giving the primary immunization before the disappearance of maternal antibody and booster after its disappearance [21]. However, the delayed immunization of offspring may increase the opportunity of infection. The second one is by shortening the interval between primary and booster immunizations of offspring. For example, as reported by Harte et al. [22], when the offspring were immunized with formalin-fixed malaria vaccine and boosted only 10 days later, the interference of maternal antibody was overcome. Yet it is not known whether the immune strategy is suitable for other vaccines. The third way is by giving high-dose vaccines for offspring, but this may cause the increase of adverse reactions or even the occurrence of death. Knudsen et al. [23] found that the mortality rate of children in Western Africa immunized with high dose of live attenuated measles vaccine was significantly higher than that of the children with standard dose of the vaccine. The fourth way is by immunizing mothers and their offspring with vaccines of different forms. Capozzo et al. [24] reported that it was workable to vaccinate female mice with the DNA vaccine pTET1pp encoding tetanus toxin fragment C (Frag C), and their offspring with the Salmonella vector carrying plasmid pTET1pp by nasal drip. The antibody titers in offspring after booster were comparable to those of maternal antibody-negative neonatal mice immunized with the same vaccine. Schlereth et al. [25] found that the immunization of cotton rats with the recombinant vesicular stomatitis virus (VSV) expressing HA gene of measles virus by nasal drip induced neutralizing antibody which could protect the animals even in the presence of antisera induced by live attenuated measles vaccine.

DNA vaccine has also been tested in search of ways to overcome the interference of maternal antibody. Manickan et al. [26] found that the maternal antibody induced by primary immunization with live herpes simplex virus (HSV) vaccine and booster with inactivated HSV vaccine interfered with the immunization of offspring with inactivated HSV vaccine, however, no interference was observed when offspring were immunized with plasmid DNA encoding glycoprotein B (gB). Premenko-Lanier et al. [27] once injected infant rhesus monkeys with the antisera induced by the infection with measles virus, then immunized with mixed DNA vaccines containing the hemagglutinin (HA), fusion protein (F) and nucleoprotein (NP) of measles virus. The result showed that the immunization with mixed DNA vaccines could overcome the interference of maternal antibody on immune response. However, different results have also been observed in other studies. Wang et al. [28] reported that the passive immunization of offspring with antisera, separated from their mothers immunized with inactivated rabies vaccine, inhibited the immune response of rabies virus glycoprotein (gp) DNA vaccine. This might be largely due to the low immunogenicity of rabies DNA vaccine. High immunogenicity of vaccine is an important factor in overcoming the interference of maternal antibody [24]. Besides this, Pertmer et al. [29] found that the maternal antibody induced by a sublethal influenza virus infection inhibited the generation of antibody after immunization of offspring with HA DNA, but did not inhibit the generation of antibody after immunization with NP DNA. The different effects were thought to be as a result of different sites at which the two kinds of DNA vaccines were expressed. The HA protein was expressed on the cell membrane and the NP in the cell. The maternal antibody could interfere with the IgG antibody induced by membrane protein but could not interfere that induced by intracellular protein.

Several mechanisms have been suggested as mediating the inhibitory influence of maternal antibodies on infant responses. But it essentially depends upon the maternal antibodies-vaccine antigen ratio at the time of immunization. The inhibition of infant responses will not occur if maternal antibodies do not persist until completion of the infant immunization schedule, as is the case for most current vaccines [30]. In this paper, we have tried several immune strategies to overcome the interference of maternal antibody with immunization of offspring. When the mothers were immunized with inactivated vaccine and their offspring with DNA vaccine, 1.0 μg and 0.1 μg of inactivated vaccine could inhibit the immunization of off-
spring with 30 μg of HA DNA vaccine. The survival rates of offspring were only 50% and 43% respectively (Table 3). The inactivated vaccine at high doses showed the inhibition to the offspring immunization with HA DNA. The result was similar to the report by Radu et al. [6]. Whereas, the maternal antibody induced by 0.01 μg of inactivated vaccine showed no inhibition to the offspring immunization with HA DNA. The survival rate of offspring after a lethal virus challenge reached 86% (6/7). On the contrary, when both female mice and their offspring were immunized with 0.01 μg of inactivated vaccine, no offspring survived the lethal virus challenge. It showed no significant inhibition of maternal antibody induced by low dose inactivated vaccine to the immunization of offspring with HA DNA.

Though the maternal immunization with inactivated vaccine partially inhibited the offspring immunization with HA DNA, it did not inhibit the offspring immunization with NA DNA. As shown in Table 3, the anti-NA antibody titers of offspring immunized with NA DNA were only slightly lower than those of offspring born to the unimmunized mothers, and the offspring were completely protected from a lethal virus challenge. The dose of inactivated vaccine showed no influence on the immunization of NA DNA in offspring. This might be due to the low NA protein content in inactivated vaccine, which induced a low titer of maternal anti-NA antibody. So the immunization of female mice with inactivated vaccine and their offspring with NA DNA was a good immune strategy to overcome the interference of maternal antibody.

Another immune strategy, i.e. the immunization of mother and the offspring with DNA vaccines encoding different antigens also showed a satisfactory result in our study. As shown in Table 4, the offspring immunized as schemed were completely protected. The anti-HA antibody titers of HA DNA-immunized offspring, born to the mothers immunized with NA DNA, were comparable to those of HA DNA-immunized offspring born to unimmunized mothers. Moreover, the protective rate of the former was significantly higher than that of the latter, which might be due to the enhancement of protective effect by maternal anti-NA antibody. Similarly, the anti-NA antibody titers in NA DNA-immunized offspring, born to the mothers immunized with HA DNA, were comparable to that of NA DNA-immunized offspring born to unimmunized mothers.

In this study the NA antibody titers were determined by fluorescent-based NI assay with the substrate 2-‘(4-methylumbeliferyl)-α-D-N-acetylneuraminic acid (4-MU). We notice there is a report showing that the assay may be unreliable and lack standardization compared with the fetuin-based assay [31]. However, we don’t think it make a big difference to draw valid conclusions in this study. Although the derived antibody titer may not be accurate because of the limitation of the NI assay, it would not influence the general changing tendency of all the antibody titers and thus would not influence the conclusions. Moreover, our conclusions are based on other factors, which we think are more important, such as survival rate and residual lung virus titer of mice, etc. The NA antibody titer determined by fluorescent-based NI assay would be further confirmed by fetuin-based assay in our future studies.

Conclusion
In this study, we designed the above experiments to explore the influence of maternal antibody on offspring and tried to find ways to overcome its inhibition effect. All the experiments were performed twice. From the results, we may conclude that, in order to avoid the interference of maternal antibody with the vaccination of offspring, the immune strategy for mothers and their offspring shall be adjusted as follows: 1) If mothers are immunized with inactivated influenza vaccine, the offspring shall be immunized with NA DNA vaccine, and the immunization with inactivated vaccine shall be avoided in offspring; 2) If mothers are immunized with influenza virus HA (NA) DNA, the offspring shall be immunized with NA (HA) DNA, and the immunization with the same DNA vaccine as that for mothers shall be avoided as far as possible.

Methods
Plasmid DNAs
Plasmids pCAGGSP7/NA and pCAGGSP7/HA were constructed by cloning the PCR products of NA and HA genes from the influenza virus strain A/PR/8/34 (PR8, H1N1) into expression vector pCAGGSP7, respectively, as described previously [32]. Plasmid pCAGGSP7 was constructed by inserting a polylinker (oligonucleotides) containing KpnI, XhoI, Clal, EcoRV, Smal, NotI and SacI sites into the EcoRI site of pCAGGS which was constructed by Niwa et al. [33]. The nucleotide sequences of NA and HA DNAs were confirmed by the dyeodeoxy method using ABI PRISM 377 DNA Sequencer (Applied Biosystems). The expressions of the encoded proteins, NA and HA, were also confirmed in 293T human embryonic kidney cells, as described previously [32]. Plasmids were propagated in Escherichia coli XL1-blue bacteria and purified using QIA-GEN purification kits (QIAGEN-tip 500, Qiagen, Chatsworth, CA).

Immunization
The female BALB/c mice in test groups were immunized twice, at an interval of 3 weeks, with the vaccine at various dosages respectively. One week after the second immunization, the female mice were bred with unimmunized...
male BALB/c mice aged 10–12 weeks in the same cage. About 15 days later, most of the females became pregnant and were then separated from the males. The offspring were grouped, 11–12 for each, and used for the subsequent test. Offspring of unimmunized mothers were produced by the same procedure.

The inactivated split-product influenza virus A/PR/8/34 (PR8, H1N1) vaccine was diluted to a volume of 200 μl with phosphate buffer saline (PBS). Adult female mice (aged 6–8 weeks) or neonatal mice (aged 1 week) were immunized i.p. with 1.0, 0.1 and 0.01 μg of inactivated influenza vaccine separately. Three weeks later, the mice were boosted with the vaccine at same dose as primed. Inactivated split-product influenza virus (PR8, H1N1) vaccine was prepared by Shanghai Institute of Biological Products (SIBP) and detected for concentration using BCA kit (Pierce).

In vivo electroporation was carried out according to the method described by Aihara and Miyazaki [34]. Adult female BALB/c mice (aged 6 to 8 weeks) and neonatal mice (aged 1 week) were immunized twice with plasmid DNA dissolved in 30 and 15 μl of Tris-EDTA buffer, respectively. After injection in the right quadriceps muscle, a pair of electrode needles with 5 mm apart was inserted into the muscle to cover the DNA injection sites and electric pulses were delivered using an electric pulse generator (Electro Square Porator T830 M; BTX, San Diego, CA). Three pulses of 100 V each, followed by three pulses of the opposite polarity, were delivered to each injection site at a rate of one pulse per second. Each pulse lasted for 50 ms.

**Infection**

One week after the second immunization, the offspring were anesthetized and challenged with 20 μl of viral suspension of mouse-adapted strain A/PR/8/34 (PR8, H1N1) [20 × 50% lethal dose (LD_{50})] by intranasal route. This infection caused rapid and widespread viral replication in the lungs and deaths of the unimmunized mice within 7 days [35].

**Specimens**

At least three mice in each group were anaesthetized with chloroform and then bled from the heart with a syringe. After bleeding, the mice were incised ventrally along the median line from the xiphoid process to the point of the chin. The trachea and lungs were taken out and washed three times by injecting with a total of 2 ml of PBS containing 0.1% BSA. The bronchoalveolar wash was used for virus titration after removing cellular debris by centrifugation [36].

**Ab assays**

The sera were collected by tail vein bleeding and used for IgG Abs assays. The titer of IgG Ab produced against HA molecules purified from PR8 virus was measured by enzyme-linked immunosorbent assay (ELISA). ELISA was performed using a 96-well microtiter plate (EIA plate, Costar, Cambridge, MA, USA) with the reagents consisting of first, HA molecules purified from the PR8 virus according to the procedure described by Phelan et al [37]; second, 2-fold serial dilutions of sera from each group of immunized or unimmunized mice; third, goat antismouse IgG Ab (γ-chain specific) (Southern Biotechnology Associates, Inc. USA) conjugated with biotin; fourth, streptavidine conjugated with alkaline phosphatase (Southern Biotechnology Associates, Inc. USA); and finally, p-nitrophenyl-phosphate. The amount of chomogen produced was measured based on absorbance at 414 nm and 405 nm in a Labsystems Multiskan Ascent Autoreader (model 354, Finland).

The inhibition assay of NA activity by Ab (NI assay) was performed with the substrate 2′-(4-methylumbeliferyl)-α-D-N-acetylneuraminic acid (4-MU). PR8 viruses (10^7 EID_{50} per ml), grown in the allantoic sac of 10-day-old chicken embryos and stored as allantoic fluid suspensions at -80°C, were employed as enzyme source. NI assay was carried out by preincubating the enzymes (25 μl) with various dilutions of antiserum (25 μl) at room temperature for 30 min before the enzyme assay. The enzyme mixtures were then incubated with the substrate solution (50 μl) containing 400 mmol/L sodium acetate (pH 6.5), 4 mmol/L calcium chloride and 2% butanol in the presence of 1 mmol/L 4-MU. After incubation at 37°C for 10–30 min, the reaction was stopped by adding a mixture (100 μl) containing 665 mmol/L glycine, 415 mmol/L sodium hydrogen carbonate and 300 mmol/L sodium chloride (pH 10.7). Levels of free 4-MU were measured by reading the fluorescence intensity on a microtiter plate fluorescence reader (Genios, Tecan) at 365 nm. Antibody-positive cut-off values were set as the mean-2 × S.D. of the fluorescence intensity of mice in control group. NI titers are expressed as the highest serum dilution that resulted in inhibition of the NA activity [38-40].

**Virus titrations**

The bronchoalveolar wash was diluted 10-fold serially starting from a dilution of 1:10, inoculated to Madin-Darby canine kidney (MDCK) cells, incubated at 37°C and examined for cytopathic effect 3 days later. The virus titer of each specimen, expressed as the fifty percent tissue culture infection dose (TCID_{50}), was calculated by Reed-Muench method [41]. The virus titer in each experimental group is represented by the mean ± S.D. of the virus titers per ml of specimens from at least 3 mice in each group.
Statistics
The results of experimental groups were evaluated by Student's t-test; if P value is less than 0.05, the difference was considered as significant. For survival, the probability was calculated by using Fisher's exact test, comparing the survival rate of mice immunized with vaccine to that of the mice in control groups. The survival patterns of the control and the immunized mice were graphed using the Kaplan-Meier survival curves. The Log Rank test was used to analyze the survival rate data. Differences were considered significant at p < 0.05.

Authors' contributions
JJC, FHZ and FF did most of the experimental work. HYC participated in the analysis of antibody. ZC conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the research funds from 1) National 973 Project (2005CB523007), 2) European commission 6th framework programme on Research, Technological Development and Demonstration (FP6-2005-SSP-5-B-INFLUENZA), 3) Chinese Academy of Sciences (KSCX-YW-R-14), 4) Hunan Provincial Science and Technology Department (2006NK2003), and 5) National Key Technology R&D Program of China (Grant No. 2006BAD06A03).

References
1. Murphy BR, Webster RG: Orthomyxoviruses. Philadelphia/New York: Lippincott Raven; 1996.
2. Hoiberg A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ, Zolfel LM, Fabian IA, Bernard BS, Kerr JD: Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003, 290(12):1608-1616.
3. Maeda T, Shintani Y, Nakano K, Terashima K, Yamada Y: Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. Pediatr Int 2004, 46(2):122-125.
4. Bickoff TC, Sherman IL, Serfling RE: Observations on excess mortality associated with epidemic influenza. JAMA 1961, 176:776-782.
5. Wilson WD, Mihalyi JE, Hussey S, Lunn DP: Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 2001, 33(7):644-650.
6. Radu DL, Antohi S, Bot A, Miller A, Mirarchi A, Bona C: Effect of maternal antibodies on influenza virus-specific immune response elicited by inactivated virus and naked DNA. Scand J Immunol 2001, 53(5):475-482.
7. van Maanen C, Bruin G, de Boer-Luijtze E, Smolders G, de Boer GF: Maternal-infant transfer of influenza-specific immunity not detectable by haemagglutination inhibition. Microbiol 1988, 54(220-221):33-47.
8. Englund J, Glezen WP, Piedra PA: Maternal immunization against viral disease. Vaccine 1998, 16(14-15):1456-1463.
9. Insel RA, Amstey M, Woodin K, Pichichero M: Maternal immunization to prevent infectious diseases in the neonate or infant. Int J Technol Assess Health Care 1994, 10(1):143-153.
10. Reuman PD, Kris RM, Ayoub EM, Small PA Jr: Maternal-infant transfer of influenza-specific immunity not detectable by haemagglutination inhibition. Microbiol 1988, 54(220-221):33-47.
11. Reuman PD, Pagannini CM, Ayoub EM, Small PA Jr: Maternal-infant transfer of influenza-specific immunity in the mouse. J Immuno 1983, 130(2):932-936.
12. Englund JA, Mbawuleke IN, Hammill H, Holleman MC, Baxter BD, Glezen WP: Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis 1993, 168(3):647-656.
13. Reuman PD, Ayoub EM, Small PA: Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J 1987, 6(4):398-403.
14. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47(RR-6):1-26.
15. Zhang F, Chen C, Fang F, Zhou Y, Wu J, Chang H, Zhang R, Wang F, Li X, Wang H, Ma G, Chen Z: Maternal Immunization with Both Hemagglutinin- and Neuraminidase-Expressing DNAs Provides an Enhanced Protection Against a Lethal Influenza Virus Challenge in Infant and Adult Mice. DNA Cell Biol 2005, 24(1):758-765.
16. Stiewen KE, Barbosa V, de Lima OS, Osipo K: The influence of maternally derived antibody on the efficacy of further attenuated measles vaccine. Infection 1978, 6(5):207-210.
17. Albrecht P, Ennis FA, Saltzman Ej, Krugman S: Persistence of maternal antibody in Bilirnavirus vaccines for influenza virus: differential effects of maternal virus challenge in infant and adult mice. J Virol 1980, 39:3709-3910.
18. Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, Lambert SB, Margolis HS: Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004, 144(3):327-332.
19. Murphy BR, Olnsted RA, Collins PL, Chanock RM, Prince GA: Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1998, 62(10):3907-3910.
20. Zanetta RA, Amaku M, Azevedo RS, Zanetta DM, Burattini MN, Massad E: Optimal age for vaccination against measles in the State of Sao Paulo, Brazil, taking into account the mother's serostatus. Vaccine 2001, 20(1–2):226-234.
21. Lagos R, Munoza A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E: Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 2003, 21(25-26):3730-3733.
22. Harte PG, Rogers N, Targett GA, Playfair JH: Maternal inhibition of malaria vaccine in mice can be overcome by giving a second dose of vaccine. Immunology 1984, 53(3):401-409.
23. Knudsen KM, Aaby P, Samb B, Butterani DM, Ferrero JF, Fine P: Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 1996, 25(3):665-673.
24. Capozzo AV, Cuberos L, Levine MM, Pasetti MF: Mucosally delivered Salmonella live vector vaccines elicit potent immune responses to a foreign antigen in neonatal mice born naïve and immune mothers. Infect Immun 2004, 72(8):4637-4646.
25. Schleureth B, Rose JK, Buonocore L, ter Meulen V, McCauley MB: DNA vaccination of neonates induces immunity despite the presence of maternal antibodies. J Virol 2000, 74(10):4652-4657.
26. Manickan E, Yu Z, Rouse BT: DNA immunization of neonates induces immunity despite the presence of maternal antibody. J Clin Invest 1997, 100(9):2371-2375.
27. Premenko-Lanier M, Rota PA, Rhodes G, Verhoeven D, Barouch DH, Lerner NW, Levin NB, McCauley MB: DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 2003, 307(1):67-75.
28. Wang Y, Xiang Z, Pasquini S, Erd HC: Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 1998, 72(3):1790-1796.
29. Pertmer TM, Oran AE, Moser JM, Madarin CA, Robinson HL: DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein. J Virol 2000, 74(17):7787-7793.
30. Siegrist CA: Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21:3406-3412.

BMC Infectious Diseases 2007, 7:118 http://www.biomedcentral.com/1471-2334/7/118

Page 10 of 11 (page number not for citation purposes)
31. Aymard M, Ferraris O, Gerentes L, Jolly J, Kessler N: Neuraminidase assays. Dev Biol (Basel) 2003, 115:75-83.
32. Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S: Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998, 16(16):1544-1549.
33. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108(2):193-199.
34. Aihara H, Miyazaki J: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16(9):867-870.
35. Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A: Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992, 22(2):477-481.
36. Li X, Fang F, Song Y, Yan H, Chang H, Sun S, Chen Z: Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. DNA Cell Biol 2000, 19(4):197-205.
37. Phelan MA, Mayner RE, Bucher DJ, Ennis FA: Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand 1980, 8(3):233-242.
38. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S: Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000, 18(28):3214-3222.
39. Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S: Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999, 80(Pt 10):2559-2564.
40. Chen J, Fang F, Li X, Chang H, Chen Z: Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 2005, 23(34):4322-4328.
41. Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/7/118/prepub